Synchronized cardioversion is a procedure similar to electrical defibrillation, in that a transthoracic electrical current is applied to the anterior chest to terminate a life-threatening or unstable tachycardic arrhythmia. Unlike defibrillation, which is used in cardiac arrest patients, synchronized cardioversion is performed on patients that still have a pulse but are hemodynamically unstable. It is used to treat both hemodynamically unstable ventricular and supraventricular rhythms.
Each year almost 350,000 Americans die from heart disease. Half of these will die suddenly, outside of a hospital because of the sudden cessation of spontaneous, organized cardiac function. The most common cause of sudden cardiac arrest in adults is pulseless ventricular tachycardia (VT) or ventricular fibrillation (VF). VT can also occur in the presence of a pulse; often it is the precursor to VF. VT is characterized by rapid, wide (greater than 0.12 seconds) QRS complexes.
Supraventricular Tachycardia (SVT) refers to a cardiac rhythm greater than 100 beats per minute, which originates above the bundle of His. SVT is characterized by rapid, narrow (less than 0.12 seconds wide) QRS complexes. Any tachycardic rhythm that does not originate in the ventricles is referred to as SVT. This includes sinus tachycardia, junctional tachycardia, reentrant tachycardias, multiple atrial tachycardia (MAT), atrial fibrillation, and atrial flutter. Although various supraventricular rhythms can cause SVT, clinically, they are treated with the same approach.
VT can be caused by coronary artery disease, hypertension, valvular heart disease, and cardiomyopathy. It can also be induced by a blow to the chest (Commotio Cordis).
SVT is usually caused by the repetitive “re-entry“ of the electrical impulse proximally, instead of propagating distally through the cardiac conduction system, due to blockages in the heart’s electrical conduction system. It can also be seen as the result of premature atrial or ventricular beats, cardiac stimulants, thyroid conditions, valvular and coronary artery disease, and as the result of digoxin toxicity.
There are no contraindications to synchronized cardioversion. The presence of a pacemaker or automated implanted cardiac defibrillator does not change the indication or performance of the procedure.
A monitor and defibrillator with synchronized function.
Under the American Heart Association's advanced cardiovascular life support (ACLS) guidelines, the identification and treatment strategies for all tachycardic rhythms involve three simple, rapid decision points. First is the identification of the rhythm as tachycardic.
Next, the tachycardic rhythm is divided into one of two categories depending on the width of the QRS complex: (1) wide-complex tachycardia (QRS width greater than 0.12 seconds) or (2) narrow-complex tachycardia (QRS width less than 0.12 seconds). All narrow-complex tachycardias are considered to be supraventricular in origin and are referred to as SVTs. Although wide-complex tachycardic rhythms can occur from sites above the ventricles (such as in supraventricular rhythms with a bundle branch block or other aberrant conduction), clinically, especially during emergent situations, wide-complex tachycardia is usually treated as ventricular in origin, as it is the most potentially life-threatening condition.
The treatment of all emergent tachycardic rhythms, whether narrow-complex or wide-complex depends on the third and final clinical determination: the presence or absence of a pulse. Pulseless rhythms are treated under the ACLS cardiac arrest algorithms: a wide-complex tachycardia would be considered to be pulseless ventricular tachycardia, which is treated the same as VF, under the VF algorithm. A narrow-complex tachycardia would be considered to be a pulseless SVT and is treated under the PEA (Pulseless Electrical Activity) algorithm.
In the presence of a pulse, the specific treatment for all tachycardic rhythms depends on one final determination: whether the pulse being generated is allowing the patient to be considered stable or unstable. In stable patients, the treatment for the underlying arrhythmia is usually medication. For the unstable patient, the treatment of choice is electricity. All tachycardic rhythms, whether wide or narrow complex, are considered to be unstable if the patient also has chest pain, dyspnea, altered mental status, hypotension, pulmonary edema, or ischemic changes on the EKG. The treatment for all unstable tachycardic rhythms is synchronized cardioversion.
Like defibrillation, synchronized cardioversion delivers a shock across the chest, either by placing a pair of manual paddles on the chest or through the application of adhesive “hands-free” pads. Most current defibrillators utilize a biphasic waveform that allows for a lower energy level to be used to achieve effective cardioversion. Because of their greater ability to terminate ventricular dysrhythmias, defibrillators utilizing biphasic waveforms are preferred to those utilizing the older, monophasic waveform.
Synchronized cardioversion differs from defibrillation in two aspects: (1) the amount of energy needed to convert the rhythm is usually less than that required for defibrillation and (2) the shock is delivered in a different part of the cardiac cycle.
When a patient is defibrillated, the energy is released through the paddles or hands-free pads immediately when the defibrillation button/s are pressed. The shock is delivered at whatever point the cardiac cycle happens to be in at that moment. If an electrical shock is provided during the relative refractory period (corresponding to the latter part of the T wave), it is possible to induce VF (the so-called “R-on-T Phenomenon”). This would result in a patient who originally had a pulse being put into cardiac arrest.
To avoid inducing cardiac arrest in a patient with a pulse, synchronized cardioversion is performed instead of defibrillation when a patient is in an SVT with a pulse but is considered unstable according to the definition above. To perform synchronized cardioversion, the defibrillator is placed into the “synchronize” mode by pressing the appropriate button on the machine. This causes the monitor to track the R wave of each QRS complex that goes by. A synchronizing marker will appear above each QRS complex, indicating that the synchronize feature is active.
The appropriate energy level is then selected, and the discharge/shock button is pressed and held. The defibrillator does not release the shock immediately. Instead, it waits for the next R-wave to appear and delivers the shock at the time of the R-wave. This allows the shock to be provided safely away from the T wave, avoiding the R-on-T phenomenon.
The recommended energy levels used to perform synchronized cardioversion vary from 50 to 200 joules. Recalling the specific energy level for a particular sub-type of unstable tachycardia is difficult, especially in an emergent situation. The safest and easiest recommendation is to start at the lowest energy level (50 joules) and if the shock is unsuccessful, double the amount of energy used. In a refractory case, you will be at 200 joules after just three shocks.
Appropriate synchronized electrical cardioversion restores the activity of the electrical conduction system of the heart and is the most effective resuscitation measure for cardiac arrest associated with ventricular fibrillation and pulseless ventricular tachycardia.
Cardioversion is performed both inside and outside the hospital and it is one technique that all healthcare professionals including nurses, pharmacists, and EMS should be familiar with. It has been shown to save lives and hence it is important to know how the device works and its indications. To ensure proficiency with cardioversion, regular updating of ATLS protocols is necessary. Education by an interdisciplinary team of specialty trained nurses and clinicians will provide the best results. [Level V]
|||Link MS, Clinical practice. Evaluation and initial treatment of supraventricular tachycardia. The New England journal of medicine. 2012 Oct 11 [PubMed PMID: 23050527]|
|||Tainter CR,Hughes PG, Commotio Cordis . 2018 Jan [PubMed PMID: 30252270]|
|||Link MS,Berkow LC,Kudenchuk PJ,Halperin HR,Hess EP,Moitra VK,Neumar RW,O'Neil BJ,Paxton JH,Silvers SM,White RD,Yannopoulos D,Donnino MW, Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015 Nov 3 [PubMed PMID: 26472995]|
|||Delaney B,Loy J,Kelly AM, The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. European journal of emergency medicine : official journal of the European Society for Emergency Medicine. 2011 Jun [PubMed PMID: 20926952]|
|||Kerber RE,Martins JB,Kelly KJ,Ferguson DW,Kouba C,Jensen SR,Newman B,Parke JD,Kieso R,Melton J, Self-adhesive preapplied electrode pads for defibrillation and cardioversion. Journal of the American College of Cardiology. 1984 Mar [PubMed PMID: 6693652]|
|||Neumar RW,Otto CW,Link MS,Kronick SL,Shuster M,Callaway CW,Kudenchuk PJ,Ornato JP,McNally B,Silvers SM,Passman RS,White RD,Hess EP,Tang W,Davis D,Sinz E,Morrison LJ, Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010 Nov 2 [PubMed PMID: 20956224]|
|||Pariaut R, Atrial Fibrillation: Current Therapies. The Veterinary clinics of North America. Small animal practice. 2017 Sep; [PubMed PMID: 28645513]|
|||Gerstein NS,McLean AR,Stecker EC,Schulman PM, External Defibrillator Damage Associated With Attempted Synchronized Dual-Dose Cardioversion. Annals of emergency medicine. 2018 Jan; [PubMed PMID: 28559035]|
|||Lewis J,Arora G,Tudorascu DL,Hickey RW,Saladino RA,Manole MD, Acute Management of Refractory and Unstable Pediatric Supraventricular Tachycardia. The Journal of pediatrics. 2017 Feb; [PubMed PMID: 27912926]|